Information  X 
Enter a valid email address

Sinclair Pharma PLC (SPH)

  Print      Mail a friend

Tuesday 04 August, 2009

Sinclair Pharma PLC

Sebclair launched in the US


                              Sinclair Pharma plc                              

             Sebclair launched in the US by Dr Reddy's Laboratories'             
                        subsidiary Promius Pharma, LLC                         

                    Launched under brand name Promiseb™ Cream                    

04 August 2009, Godalming, UK: Sinclair Pharma plc (SPH.L), the international
specialty pharma company, today announced its treatment for seborrheic
dermatitis has been launched in the United States by Promius Pharma, the
dermatology division of Dr Reddy's Laboratories, Inc. Sinclair licensed the
exclusive rights for the USA of its seborrheic dermatitis product, Sebclair, to
Dr Reddy's in September 2007. Dr Reddy's is marketing the product under the
brand name of Promiseb Cream.

Promiseb / Sebclair Cream is a non-steroidal, prescription only cream for the
treatment of seborrheic dermatitis, which has demonstrated both
anti-inflammatory and antifungal properties.

In the United States, 3 - 5% of the general population (307M) suffers from
seborrheic dermatitis and Sinclair will receive royalty payments based on the
net sales of Promiseb. Promius Pharma began promotion of Promiseb Cream at the
Summer Meeting of the American Academy of Dermatology in Boston, Massachusetts
last week and has a sales force visiting 7000 dermatologists, who generate 65
to 70% of prescriptions in seborrheic dermatitis, to market this product.

Jeff Wasserstein, President of Promius Pharma, said "We are very excited about
Promiseb Cream because it has the potential to replace both anti-inflammatory
and antifungal treatments in patients with seborrheic dermatitis. In a clinical
study Promiseb was shown to have efficacy comparable to desonide cream 0.05% at
days 14 and 28 with fewer relapses.

"Promiseb Cream also has an excellent safety profile with no restrictions on
age, duration of use or application on the face." He continued, "We are very
enthusiastic about this product because our clinical research shows that
Promiseb Cream may be used as a first-line treatment for seborrheic flares and
for long-term maintenance"

Sebclair cream is registered in the EU and has so far been launched in France,
Italy & Spain through Sinclair's own operations.

Commenting on today's announcement, Dr Michael Flynn, Chief Executive of
Sinclair Pharma, said:


"The launch of Promiseb in the United States further expandsthe presenceof
Sinclair products in th US market, bringing the total to seven productsnow
soldinthe US ahead of the planned launch of our flagship product,
Decapinol,later this financial year. Dr Reddy's Promius Pharmais a dynamic
company which has built a strong dermatology portfolio and is well positioned to
market Promiseb in the US.

We believe there is great potential on the market for a non-steroidal cream such
as this, providing a safer alternative to existing treatments."


                                   - ends -                                    

For further information please contact:

Sinclair Pharma plc Tel: +44 (0) 1483 410 600

Dr Michael Flynn, CEO

Jerry Randall, CFO

Mariyam Rawat, Director of Communications & Investor relations

Email: [email protected]

Capital MS&L

Mary Clark, Joanna Whineray Tel +44 (0)20 7307 5337

Notes to Editors:

About Seborrheic Dermatitis and SebclairTM

Seborrheic dermatitis is a common skin condition that affects areas of the body
with a particularly high concentration of sebaceous glands. This may include
the eyebrows, bridge of the nose, naso-labial folds, ears and chest. It
manifests as erythema (reddening), which progresses to flakiness and at its
most severe, crusting of the skin. Seborrheic dermatitis of the scalp is also
particularly common, and in its mildest form may be referred to as dandruff.

Seborrheic dermatitis is a common condition characterized by flaky, red skin.
It is most common in men and is present in up to 5% of the adult population
with over 1.5 million visits to physicians for seborrheic dermatitis (IMS-NDTI,
2006) whilst there is also a significant spend on over-the-counter products.

Sebclair™ cream is registered in the US and EU and addresses the skin market.
Sebclair shampoo, recently registered in the EU, addresses the scalp sector of
the market. Seborrheic dermatitis also often appears as cradle cap in infants
of around six months. It usually clears by 18 months but can be a persistent
problem during this time. After infancy, the condition is most common in middle
age or older people. It may also be associated with a poor diet and obesity,
HIV and neurological conditions such as Parkinson's disease.

At present there are various approaches to the management of seborrheic
dermatitis but there is no `gold-standard' product. Many of the treatments
focus on the potential presence of fungi or other organisms on the surface of
the skin, and topical corticosteroids are also frequently employed. Although
topical corticosteroids are commonly used, they are also disliked, as these
drugs may cause atrophy of the skin and are usually restricted to short
treatment periods, particularly on facial skin. Emollients, lithium-based and
salicylic acid-based creams are considered to improve the condition.

Other seborrheic dermatitis treatments

Seborrheic dermatitis is frequently treated with topical corticosteroids.
However, this group of drugs may have unfavourable side effects, especially
when used long-term or on sensitive areas of skin such as the face, hands, or
on children. These effects vary from mild and reversible thinning, to
irreversible telangiectasiae (fine blood vessels becoming visible at the
surface of the skin) and striae distensae (marks similar in appearance to
`stretch marks'). Steroids' effectiveness may also become less effective with
continued use, which may lead to the escalation to a more potent steroid. There
may also be a risk of growth suppression and adrenal suppression in children
with the use of topical steroidsvi. SebclairTM does not contain
corticosteroids. Other topical agents used to treat seborrhheic dermatitis
include antifungal and other antimicrobial products.

About Sinclair Pharma Plc www.sinclairpharma.com

Sinclair Pharma plc is an international specialty pharmaceutical company
providing solutions to treat dermatological, oral care & gynaecological
diseases through advanced surface technology and innovative delivery system. It
has a growing sales and marketing operation in France, Italy, Spain and
Portugal, and a complementary marketing partner network that spans more than 80
countries.

About Sebclair

Sebclair® is indicated to manage and relieve the itching, burning, scaling and
pain experienced with seborrhoeic dermatitis. It is a non-steroidal, barrier
enhancing, mildly keratolytc composition of ingredients formulated to help
normalize skin physiology which has been altered by seborrhoeic dermatitis and
cradle cap in infants.

About Promius Pharma LLC www.promiuspharma.com

Promius Pharma is a wholly owned, branded specialty company, of Dr. Reddy's
Laboratories Inc. It is located in Bridgewater, NJ.

"Safe Harbour" Statement under the US Private Securities Litigation Reform Act
of 1995: Some or all of the statements in this document that relate to future
plans, expectations, events, performances and the like are forward-looking
statements, as defined in the US Private Securities Litigation Reform Act of
1995. Actual results of events could differ materially from those described in
the forward-looking statements due to a variety of factors.

a d v e r t i s e m e n t